[Laboratory and clinical studies on meropenem in pediatrics]
Related Experiment Videos
1Department of Pediatrics, Anjo Kosei Hospital.
Abstract:
Laboratory and clinical studies on meropenem (MEPM), a new carbapenem antibiotic, were carried out in the field of pediatrics. The results obtained are summarized below. 1. The antibacterial activities of MEPM against clinically isolated organisms in our department were generally high. 2. After 30 minutes intravenous drip infusion of MEPM at a dose of 20 mg/kg to 2 children, the mean peak plasma level of MEPM was 32.7 micrograms/ml at the end of infusion with a mean half-life of 1.45 hours. The mean cumulative urinary recovery rate in the first 6 hours after infusion was 43.6%. 3. Fifteen patients with various bacterial infections were treated with MEPM. The clinical efficacy rate was 100% and the bacteriological efficacy rate was 95.2%. 4. No side effects were observed except in 1 case of mild diarrhea. Some abnormal laboratory test results were obtained, but they were mild with slight elevations of GOT and GPT in 2 cases.
Insights
Meropenem (MEPM), a new carbapenem antibiotic, shows high antibacterial activity and efficacy in pediatric patients. Clinical studies indicate a 100% clinical efficacy and 95.2% bacteriological efficacy with minimal side effects.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Clinical Microbiology
Background:
- Meropenem (MEPM) is a novel carbapenem antibiotic.
- Pediatric applications of MEPM require thorough investigation.
Purpose of the Study:
- To evaluate the laboratory and clinical efficacy of meropenem in pediatric patients.
- To assess the pharmacokinetic profile of meropenem in children.
Main Methods:
- In vitro susceptibility testing of clinically isolated organisms against MEPM.
- Pharmacokinetic analysis of MEPM following intravenous infusion in pediatric subjects.
- Clinical trial evaluating MEPM treatment in pediatric patients with bacterial infections.
Main Results:
- MEPM demonstrated high in vitro antibacterial activity against clinical isolates.
- Pharmacokinetic data showed a mean peak plasma level of 32.7 µg/ml and a half-life of 1.45 hours in children.
- 100% clinical efficacy and 95.2% bacteriological efficacy were observed in 15 pediatric patients.
- Adverse events were minimal, with one case of mild diarrhea and transient elevations in liver enzymes (GOT, GPT) in two patients.
Conclusions:
- Meropenem exhibits potent antibacterial activity and favorable pharmacokinetic properties in pediatric patients.
- MEPM is a safe and effective treatment option for various bacterial infections in children.
- Further studies are warranted to explore the full therapeutic potential of meropenem in pediatric populations.